BRISTOL-MYERS SQUIBB DOWNSIZING PHARMACEUTICAL GROUP BY 10%
Executive Summary
BRISTOL-MYERS SQUIBB DOWNSIZING PHARMACEUTICAL GROUP BY 10%, or approximately 3,000 of the group's 30,000 employees worldwide. Bristol-Myers Squibb announced Jan. 4 that it is restructuring and realigning its businesses, with the focus mainly on the pharmaceutical sales forces and marketing. The 10% reduction in the Pharmaceutical Group is the brunt of a corporate downsizing that is expected to reduce BMS' employee levels by "approximately 5,000" worldwide "during the next two years," the company said. The Pharmaceutical Group will account for 60% of that 5,000-person cutback.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth